The guideline group recommends shared decision making when prescribing each component of HT with consideration of patient preference, contraceptive needs, and presence of co-morbidities.	GPP
Different estrogens/progestogens have variable metabolic and other effects, which should be taken into consideration when personalizing care in POI.	STRONG ⊕⊕◯◯
The guideline group recommends that HCPs and women should be aware that compounded ‘bio-identical’ preparations of estrogen and progesterone are not recommended due to lack of data regarding efficacy and safety.	GPP
Women with POI should be advised that adherence to HT is important to minimize long-term health risks and therefore long-term follow-up is needed.	STRONG ⊕⊕◯◯